Zachary Hornby

Ignyta Operating, Inc. develops molecular diagnostics for cancer and immunology. It is a biotechnology company developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. The firm's products include TrailblazeDx for RA, TrailblazeTx for RA, TrailblazeDx for SLE, TrailblazePx for SLE and TrailblazeTx for SLE. The company was founded in August 2011 by Jonathan E. Lim and Gary S. Firestein and is headquartered in San Diego, CA.

Independa, Inc. provides software-based solution. It allows caregivers and family members to video chat, send Facebook messages and photos, set up appointments and medication reminders, and play games with their older loved ones. The firm also offers blood-pressure monitoring devices, scales and glucometers, and can serve as a door sensor and emergency-alert system. The company was founded by Kian Saneii in 2009 and is headquartered in San Diego, CA.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

City Hill Ventures LLC (City Hill Ventures) is a venture capital firm founded in 2010 by Jonathan Lim. The firm is headquartered in San Diego, California.

Novome Biotechnologies, Inc. operates as a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company was founded by William DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ in 2016 and is headquartered in South San Francisco, CA.

Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024.